References
- SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
- Early Breast Cancer Trialists’ Collaborative GEffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet200536594721687171715894097
- ClemonsMDansonSHamiltonTGossPLocoregionally recurrent breast cancer: incidence, risk factors and survivalCancer Treat Rev2001272678211319846
- MartinoMBallestreroAZambelliALong-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registryBone Marrow Transplant201348341441822863724
- Breast Cancer Facts & Figures 2015–2016Society ACAtlanta, GAAmerican Cancer Society, Inc.;2015 Available from: https://www.cancer.org/research/cancer-facts-statistics/breast-cancer-facts-figures.htmlAccessed March 28, 2018
- ReinertTBarriosCHOptimal management of hormone receptor positive metastatic breast cancer in 2016Ther Adv Med Oncol20157630432026557899
- Breast Cancer Treatment (PDQ®)–Health Professional VersionBethesda, MDNational Cancer Institute2017
- JohnstonSRNew strategies in estrogen receptor-positive breast cancerClin Cancer Res20101671979198720332324
- Gonzalez-AnguloAMMorales-VasquezFHortobagyiGNOverview of resistance to systemic therapy in patients with breast cancerAdv Exp Med Biol200760812217993229
- FinnRSCrownJPLangIThe cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2−negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studyLancet Oncol2015161253525524798
- BaselgaJCamponeMPiccartMEverolimus in postmenopausal hormone-receptor-positive advanced breast cancerN Engl J Med2012366652052922149876
- HortobagyiGNStemmerSMBurrisHARibociclib as first-line therapy for hr-positive, advanced breast cancerN Engl J Med2016375181738174827717303
- PhillippDAdesAEDiasSPalmerSAbramsKRWeltonNJNICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICEUnit DSSheffield2016
- SignorovitchJESikiricaVErderMHMatching-adjusted indirect comparisons: a new tool for timely comparative effectiveness researchValue Health201215694094722999145
- SuttonAAdesAECooperNAbramsKUse of indirect and mixed treatment comparisons for technology assessmentPharmacoeconom-ics2008269753767
- TremblayGLivingsCCroweLKapetanakisVBriggsADetermination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancerClinicoecon Outcomes Res2016832333327418847
- SignorovitchJSwallowEKantorEEverolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparisonExp Hematol Oncol2013213224314093
- SignorovitchJEBettsKAReichmannWMOne-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparisonCurr Med Res Opin201531231532225356603
- SikiricaVFindlingRLSignorovitchJComparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodologyCNS Drugs2013271194395323975660
- FinnRSMartinMRugoHSPalbociclib and letrozole in advanced breast cancerN Engl J Med2016375201925193627959613
- LargillierRFerreroJMDoyenJPrognostic factors in 1038 women with metastatic breast cancerAnn Oncol200819122012201918641006
- HigginsJPTGreenSCochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]The Cochrane Collaboration2011 Available from http://handbook.cochrane.orgAccessed MArch 28 2018
- BucherHCGuyattGHGriffithLEWalterSDThe results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trialsJ Clin Epidemiol19975066836919250266